4.5 Article

A Clinical Prediction Model to Distinguish Maturity-Onset Diabetes of the Young From Type 1 and Type 2 Diabetes in the Chinese Population

期刊

ENDOCRINE PRACTICE
卷 27, 期 8, 页码 776-782

出版社

ELSEVIER INC
DOI: 10.1016/j.eprac.2021.05.002

关键词

maturity-onset diabetes of the young; prediction model; GCK; HNF1A

资金

  1. National Key R&D Programmes of China [2017YFC1309603]
  2. National Key Research and Development Program of China [2016YFA0101002, 2018YFC2001100]
  3. National Natural Science Foundation of China [81170736, 81570715, 81870579]
  4. Beijing Natural Science Foundation [7202163]
  5. Medical Epigenetics Research Center, Chinese Academy of Medical Sciences [2017PT31036, 2018PT31021]
  6. Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences [CIFMS2017-I2M-1-008]
  7. Xuanwu Hospital Science Program for Fostering Young Scholars [QNPY2020014]

向作者/读者索取更多资源

The research proposed using numerous and weighted clinical traits as key indicators for genetic testing to predict the probability of MODY in the Chinese population. A prediction model based on data from 306 patients was developed, showing excellent discrimination in distinguishing MODY patients from T1D and T2D patients. Specific biomarkers were identified for different MODY subtypes to improve the identification process.
Objective: Genetic detection for the diagnosis of maturity-onset diabetes of the young (MODY) in China has low sensitivity and specificity. Better gene detection is urgently needed to distinguish testing subjects. We proposed to use numerous and weighted clinical traits as key indicators for reasonable genetic testing to predict the probability of MODY in the Chinese population. Methods: We created a prediction model based on data from 306 patients, including 140 patients with MODY, 84 patients with type 1 diabetes (T1D), and 82 patients with type 2 diabetes (T2D). This model was evaluated using receiver operating characteristic curves. Results: Compared with patients with T1D, patients with MODY had higher C-peptide levels and negative antibodies, and most patients with MODY had a family history of diabetes. Different from T2D, MODY was characterized by lower body mass index and younger diagnostic age. A clinical prediction model was established to define the comprehensive probability of MODY by a weighted consolidation of the most distinguishing features, and the model showed excellent discrimination (areas under the curve of 0.916 in MODY vs T1D and 0.942 in MODY vs T2D). Further, high-sensitivity C-reactive protein, glycated hemoglobin A1c, 2-h postprandial glucose, and triglyceride were used as indicators for glucokinase-MODY, while triglyceride, high-sensitivity C-reactive protein, and hepatocellular adenoma were used as indicators for hepatocyte nuclear factor 1-alpha MODY. Conclusion: We developed a practical prediction model that could predict the probability of MODY and provide information to identify glucokinase-MODY and hepatocyte nuclear factor 1-alpha MODY. These results provide an advanced and more reasonable process to identify the most appropriate patients for genetic testing. (C) 2021 AACE. Published by Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据